| Outcome Measures: |
Primary: P2Y12 reaction unit (PRU), The PRU by VerifyNow P2Y12 assay at 2-4 hours after the first study drug dose on day 15±2, 15±2 days | Secondary: P2Y12 reaction unit (PRU) (before), The PRU by VerifyNow P2Y12 assay before the first study drug dose on day 15±2, 15±2 days|Percent inhibition (% Inhibition), The % Inhibition by VerifyNow P2Y12 assay at 2-4 hours after the first study drug dose on day 15±2, 15±2 days|Percent inhibition (% Inhibition) (before), The % Inhibition by VerifyNow P2Y12 assay before the first study drug dose on day 15±2, 15±2 days|High on-treatment platelet reactivity (HOPR), The rate of HOPR by VerifyNow P2Y12 assay at 2-4 hours after the first study drug dose on day 15±2, 15±2 days|High on-treatment platelet reactivity (HOPR) (before), The rate of HOPR by VerifyNow P2Y12 assay before the first study drug dose on day 15±2, 15±2 days|Non-coronary artery bypass graft (CABG) related major bleeding, The rate of non-CABG related major bleeding according to Platelet Inhibition and Patient Outcome (PLATO) study definition up to day 15±2., 15±2 days|Non-coronary artery bypass graft (CABG) related major or minor bleeding, The rate of non-CABG related major or minor bleeding according to PLATO definition up to day 15±2., 15±2 days|Non-coronary artery bypass graft (CABG) related major or minor or minimal bleeding, The rate of non-CABG related major or minor or minimal bleeding according to PLATO definition up to day 15±2., 15±2 days
|
